Arcutis Biotherapeutics (ARQT) Stock Looks Expensive Despite Its Huge Three Year Run
Arcutis Presents New Caregiver-Reported Outcomes Data Supporting ZORYVE® (roflumilast) Cream 0.05% for Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months at the ACAAI Annual Scientific Meeting
Arcutis Biotherapeutics Presents New Caregiver-Reported Outcomes Data From INTEGUMENT-INFANT Trial Supporting ZORYVE Cream 0.05%, At ACAAI Annual Scientific Meeting
Arcutis Biotherapeutics, Inc. 2026 Q3 - Results - Earnings Call Presentation
Arcutis Biotherapeutics Inc (ARQT) (Q3 2026) Earnings Call Highlights: Revenue Surges 45% to ...
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics (ARQT) Raised 2026 Sales Guidance, Is The Upside Already Priced In?
TD Cowen Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40
Arcutis Biotherapeutics, Inc. Q3 2026 Earnings Call Summary
Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis
Arcutis Biotherapeutics Initiates Enrollment In Its INTEGUMENT-3 Trial To Evaluate ZORYVE To Treat Atopic Dermatitis
Arcutis Biotherapeutics Q3 Earnings Call Highlights
Arcutis Biotherapeutics, Inc. (ARQT) Q3 2026 Earnings Call Transcript
Arcutis Biotherapeutics, Inc. (ARQT) Misses Q3 Earnings Estimates
Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update
Arcutis Biotherapeutics Announces $200M At-The-Market Common Stock Offering
Arcutis Biotherapeutics Q3 2026 Earnings Call Transcript
Arcutis Biotherapeutics Q3 EPS $0.06 Misses $0.12 Estimate, Sales $143.919M Beat $142.592M Estimate
Arcutis Appoints Rob Scott, MD to Board of Directors
Arcutis Biotherapeutics (NASDAQ:ARQT): High Growth Momentum Meets a Breakout Setup
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.